Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

被引：154

作者：

Gattermann, Norbert ^{[1
]}

Finelli, Carlo ^{[2
]}

Della Porta, Matteo ^{[3
]}

Fenaux, Pierre ^{[4
]}

Ganser, Arnold ^{[5
]}

Guerci-Bresler, Agnes ^{[6
]}

Schmid, Mathias ^{[7
]}

Taylor, Kerry ^{[8
]}

Vassilieff, Dominique ^{[9
]}

Habr, Dany ^{[10
]}

Domokos, Gabor ^{[11
]}

Roubert, Bernard ^{[11
]}

Rose, Christian ^{[12
]}

机构：

[1] Heinrich Heine Univ, Dept Haematol Oncol & Clin Immunol, D-40225 Dusseldorf, Germany

[2] St Orsola Marcello Malpighi Hosp, Bologna, Italy

[3] Univ Pavia, Sch Med, IRCCS Policlin S Matteo, I-27100 Pavia, Italy

[4] Univ Paris 13, Hop Avicenne, AP HP, Bobigny, France

[5] Hannover Med Sch, D-30623 Hannover, Germany

[6] CHU Brabois, Vandoeuvre Les Nancy, France

[7] Univ Hosp, Ulm, Germany

[8] Mater Hosp, Brisbane, Qld, Australia

[9] Univ Paris 05, Hop Cochin, AP HP, Paris, France

[10] Novartis Pharmaceut, E Hanover, NJ USA

[11] Novartis Pharma AG, Basel, Switzerland

[12] Hop St Vincent de Paul, Lille, France

来源：

LEUKEMIA RESEARCH | 2010年 / 34卷 / 09期

关键词：

Myelodysplastic syndromes; Deferasirox; Serum ferritin; Labile plasma iron; Iron chelation therapy; LABILE PLASMA IRON; OXIDATIVE STRESS; SERUM FERRITIN; MDS PATIENTS; CHELATION; THERAPY; ANEMIAS; MULTICENTER; THALASSEMIA; LPI;

D O I：

10.1016/j.leukres.2010.03.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500 ng/mL, similar to 50% were chelation-naive. Overall median serum ferritin decreased significantly at 1 year (p = 0.002). Decreases occurred irrespective of whether patients were chelation-naive or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p < 0.0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：1143 / 1150

页数：8

共 28 条

[1]

Medical progress: Disorders of iron metabolism [J].

Andrews, NC .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (26) :1986-1995

[2]

[Anonymous], BLOOD

[3]

[Anonymous], HEMATOL ONCOL CLI S1

[4]

Consensus statement on iron overload in myelodysplastic syndromes [J].

Bennett, John M. .

AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (11) :858-861

[5]

BRISSOT P, 2007, INT BIOIRON SOC

[6]

LPI-labile plasma iron in iron overload [J].

Cabantchik, ZI ;

Breuer, W ;

Zanninelli, G ;

Cianciulli, R .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (02) :277-287

[7]

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias [J].

Cappellini, Maria Domenica ;

Porter, John ;

El-Beshlawy, Amal ;

Li, Chi-Kong ;

Seymour, John F. ;

Elalfy, Mohsen ;

Gattermann, Norbert ;

Giraudier, Stephane ;

Lee, Jong-Wook ;

Chan, Lee Lee ;

Lin, Kai-Hsin ;

Rose, Christian ;

Taher, Ali ;

Thein, Swee Lay ;

Viprakasit, Vip ;

Habr, Dany ;

Domokos, Gabor ;

Roubert, Bernard ;

Kattamis, Antonis .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (04) :557-566

[8]

Labile plasma iron in iron overload: redox activity and susceptibility to chelation [J].

Esposito, BP ;

Breuer, W ;

Sirankapracha, P ;

Pootrakul, P ;

Hershko, C ;

Cabantchik, ZI .

BLOOD, 2003, 102 (07) :2670-2677

[9]

The Role of Oxidative Stress in Hemolytic Anemia [J].

Fibach, Eitan ;

Rachmilewitz, Eliezer .

CURRENT MOLECULAR MEDICINE, 2008, 8 (07) :609-619

[10]

GHOTI H, 2010, HAEMATOLOGICA

← 1 2 3 →